Catherine Sabatos-Peyton, Ph.D., is Larkspur Biosciences’ Chief Executive Officer and member of the board of directors. Prior to joining Larkspur in 2021, Catherine was Executive Director and Head of Immune Modulation at Novartis Institutes for BioMedical Research (NIBR), overseeing strategy and development of immunotherapy programs (small molecule and biologics) from preclinical validation and translational research, through development into Ph1-3 clinical trials for molecules including the Novartis checkpoint antibodies and multiple novel tumor microenvironment modulating therapies. Catherine joined Novartis in 2014 from the acquisition of CoStim Pharmaceuticals where she was Director of Immunology, developing the cancer checkpoint antibodies that became part of the Novartis pipeline. Catherine was a Fulbright Fellow at the University of Oxford. She earned her Ph.D. from the Division of Medical Sciences at Harvard University where she was part of the team that first discovered TIM-3, now understood as a critical immune and leukemic stem cell modulator in AML and MDS. Catherine went on to a postdoctoral fellowship at UCSF, followed by a fellowship at the University of Bristol (funded by the UK Multiple Sclerosis Society).